Reduction of antiarrhythmic drug use in patients receiving implantable cardioverter defibrillators

PACE - Pacing and Clinical Electrophysiology

Volumn 19, Issue 1, 1996, Pages 61-64

  Sperry, Robert E ^a   Stambler, Bruce S ^a   Wood, Mark A ^a   Cycan, Alan ^a   Ellenbogen, Kenneth A ^a,b  

^a HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiarrhythmic agents; implantable cardioverter defibrillators; ventricular arrhythmias

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE;

ANTI-ARRHYTHMIA AGENTS; DATABASES, FACTUAL; DEFIBRILLATORS, IMPLANTABLE; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0030022620     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1996.tb04791.x     Document Type: Article

References (10)

1. Echt DS, Leibson PR, Mitchell LB, et al. Mortality and morbidity in patient's receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324(12): 781-788.
2. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327(4):227-228.
3. Morganroth J, Coin JE, Quinidine related mortality in the short to medium term treatment of ventricular arrhythmias. A Meta Analysis. Circulation 1991; 84(5):1977-1983.
4. Newman D, Sauve MJ, Herre J, et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69:099-903.
5. Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter defibrillators. Circulation 1991; 84:558-500.
6. Hawthorne HR, Wood MA, Stambler BS, et al. Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillation implantation? PACE 1993; 16: 2241-2249.
7. Nalos PC, Kass RM, Gang ES, et al. Life-threatening postoperative pulmonary complications in patients with previous amiodarone pulmonary toxicity undergoing cardiothoracic operations. J Thorac Cardiovasc Surg 1987; 93:904-912.
8. Manz J, Jung W, Lüderitz B. Interactions between drugs and devices: Experimental and clinical studies. Am Heart J 1994; 127 (4 Pt. 2):978-984.
9. Dolack GL. Clinical predictors of implantable cardioverter defibrillator shocks (results of CASCADE Trial). Cardiac Arrest in Seattle, Conventional Versus Amiodarone Drug Evaluation. Am J Cardiol 1994; 73(4):237-241.
10. 4210 PMA Submission. Section VI. Clinical Report. Telectronics, Denver, Colorado.